Viveve Medical Inc.

Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the GENEVEVE™ treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in one 30-minute in-office session.

International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications from over 55 countries. Consistent with these approvals, Viveve is seeking an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to conduct a pivotal study on use of the device for improvement in sexual function. Currently, in the United States, the Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis.

InControl Products by Viveve are FDA cleared medical devices that treat stress, urge, and mixed incontinence conditions and products to improve pelvic floor strength. Viveve exclusively distributes InControl Medical's products to healthcare providers in the United States.

Expert Comments:

Cowen analyst Dr. Joshua Jennings highlighted this medical device firm’s Q1/18 developments and financial results.
read more >
Brian Marckx, Zacks Small-Cap Research (5/17/18)
"Viveve Medical Inc.'s management reiterated their previously issued 2018 revenue guidance in the range of $22–24M (+44–57%). . .Q1/18 total revenue was $3.7M, up 22% year over year. . .console placements totaled 53 units including 38 U.S. and 15 outside the U.S. Treatment tips shipped totaled 5,400, approximately 1,900 (35%) of which were included as part of the stress urinary incontinence buy-one-get-one-free program." -Zacks Small-Cap Research

Josh Jennings, Cowen & Co. (5/11/18)
"Viveve Medical Inc.'s Q1/18 report had several new developments, most notably, the appointment of Scott Durbin to the CEO spot. Although sales lagged our estimate, VIVE recently retooled its commercial team strategy, which likely caused the 1Q shortfall. VIVE reiterated its 2018 revenue guidance and has intensified its efforts in incontinence, an indication that's 100% incremental to the laxity opportunity. . .the company improved traction with its hybrid direct distributor sales model in select countries in Europe and gained new regulatory approvals in three Latin American countries."

Anthony Vendetti, Maxim Group (5/11/18)
"Yesterday, after the market close, Viveve Medical Inc. reported Q1/18 revenue of $3.7M, up 21.6% year over year. . .53 Geneveve systems shipped in Q1/18, including 38 in North America, bringing the total commercial installed base to 497 systems. The company also sold approximately 5,400 consumable treatment tips in Q1/18."

Jeff Cohen, Ladenburg Thalmann (5/11/18)
"Viveve Medical Inc. expanded the commercial sales force in Q1/18 to a total of 42 members; the additions included four sales directors, 24 capital representatives and five associate sales representatives. Four practice management representatives were also added during the quarter to drive utilization and provide physician support; the expanded sales force is expected to significantly drive revenue for the remainder of the year to achieve the 2018 revenue guidance previously announced."

The company performed strongly in the U.S. and the Asia Pacific region.
read more >
Brian Marckx, Zacks Small-Cap Research (3/28/18)
"Viveve Medical Inc.'s Q4/17 total revenue was $5.1M, up 108% year over year, up 25% from Q3/17 and largely in line with our $5.2M pre-Q4/17 preannouncement estimate. The company has now grown revenue on a sequential basis for 13 consecutive quarters." -Zacks Small-Cap Research

Jeff Cohen, Ladenburg Thalmann (3/19/18)
"This morning, Viveve Medical Inc. announced U.S. Food and Drug Administration approval of the investigational device exemption application to conduct the VIVEVE II clinical trial. . .it is anticipated to begin enrollment in H2/18. . .VIVEVE II will evaluate safety and efficacy as the primary endpoints of the cryogen-cooled monopolar radiofrequency technology in treatment of vaginal introitus in women following vaginal childbirth."

Anthony Vendetti, an analyst with Maxim Group, shared the results both of a pilot study for stress urinary incontinence and of a recent equity raise by this company.
read more >
A company marketing a product designed to enhance women's sexual function announced preliminary financial results for Q4/17 that caught the attention of several analysts.
read more >
Following the company's release of its latest financial report, three analysts weighed in on the results.
read more >

More Expert Comments

Experts Following This Company

Jeff Cohen, Analyst – Ladenburg Thalmann
Josh Jennings – Cowen & Co.
Brian Marckx, CFA – Zacks Small-Cap Research
Anthony Vendetti – Maxim Group

The information provided above is from analysts, newsletters, the company and other contributors.

Viveve Medical Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
First clinically efficacious technology addressing a $7B market opportunity with limited to no competition
Seasoned medical device executive team with a history of significant successes
Highly undervalued stock with >90% ownership from high quality, institutional healthcare investors